To develop novel therapeutics targeting underserved human eye disease, helping those who currently have few or no treatment options.

Our Vision

Opticin Therapeutics


April 2017 - Opticin Therapeutics to Present at BioTrinity 2017, Europe’s leading Biopartnering and Investment Conference, to be held on 8-10 May at the Novotel  London West

Jun 2016 - Opticin Therapeutics is shortlisted as a finalist in the Royal Society of Chemistry's Emerging Technologies competition 

Pioneering Research Into Vasoproliferative Eye Disease